Cambridge Healthtech Institute’s 9th Annual

Antibodies for Cancer Therapy
( がん治療のための抗体 )

Driving Breakthrough Therapies

2019年4月8〜9日


Antibodies have great specificity and potency to be directed against cancer. The latest wave of novel antibody designs leverages our current knowledge of the tumor microenvironment and immune cell populations and our understanding of biology for selective targeting. Don’t miss the Ninth Annual Antibodies for Cancer Therapy conference for a meeting of the great thought leaders in the field to share creative ideas and advance clinical progress.

Preliminary Agenda

KEYNOTE PRESENTATION: Using Tumor Reactive mAb and IL2 to Sequentially Engage Innate and Adaptive Anti-Tumor Immunity

Paul M. Sondel, MD, PhD, Reed and Carolee Walker Professor of Pediatrics, Human Oncology, and Genetics, Director of Research, UW Division of Pediatric Hematology, Oncology and BMT, UW Carbone Cancer Center and American Family Children’s Hospital, University of Wisconsin

KEYNOTE PRESENTATION: Role of HLA Antigen Presentation in Resistance to Immune Checkpoint Blockade

F. Stephen Hodi, MD, Professor, Medicine, Harvard Medical School; Professor, Medical Oncology, Dana-Farber Cancer Institute; Sharon Crowley Martin Chair, Melanoma, Dana-Farber Cancer Institute

TARGETING B7/H3: COMPARISON OF DIFFERENT APPROACHES

Genetic Alteration of the Bispecific Antibody Platform to Create Trispecific NK Cell Engagers (TriKes) Targeting B7-H3

Daniel A. Vallera, PhD, Lion Scholar and Professor, Director, Section on Molecular Cancer Therapeutics; Professor of Therapeutic Radiology, University of Minnesota Masonic Cancer Center 

Past, Present and Future of Omburtamab for the Treatment of B7H3(+) Tumors

Mahiuddin Ahmed, PhD, CSO, Y-mAbs Therapeutics

New Findings, New Progress with ADC Directed against B7/H3

Deryk Loo, PhD, Director, Macrogenics

Streamlined Discovery and Production of Therapeutic Antibodies

Meelis Kadaja, PhD, MBA, Director of Business Development, Icosagen Cell Factory


MESOTHELIN-TARGETED THERAPIES IN SOLID TUMORS

A Two-in-One Approach to Target Solid Tumors – CAR T-Cells and Checkpoint Blockade

Prasad S. Adusumilli, MD, FACS FCCP, Deputy Chief and Associate Attending, Thoracic Surgery; Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center (CTC), Memorial Sloan-Kettering Cancer Center; Associate Professor, Cardiothoracic Surgery, Weill Cornell Medical Center

Immunotoxins Targeting Mesothelin for Cancer Therapy

Raffit Hassan, MD, Chief, Thoracic and GI Malignancies Branch; Head, Thoracic Oncology Section, Center for Cancer Research, NCI

EMERGING TARGETS

Anti-BCMA Recombinant Immunotoxins Are Highly Active Agents for Myeloma Therapy

Ira H. Pastan, MD, Co-Chief, Laboratory of Molecular Biology; NIH Distinguished Investigator; Head, Molecular Biology Section

Development of Next-Generation Immune Modulators

René Hoet, PhD, CSO, Imcheck Therapeutics

Phase I CD123 CAR T-Cell Trial in Adults with Relapsed/Refractory AML

L. Elizabeth Budde, MD, PhD, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope

Immune-Based Therapies in Acute Myeloid Leukemia

Naval G. Daver, MD, Associate Professor, Leukemia Department, MD Anderson Cancer Center

Strategies and Challenges for Targeting CD47 to Enhance Antitumor Immunity

David D. Roberts, PhD, Senior Investigator, Head, Biochemical Pathology Section, Laboratory of Pathology, CCR, NCI

Antibody Protein Sequencing with Mass Spectrometry

Mingjie Xie, CEO, Rapid Novor, Inc.


Harbour-BiomedLuncheon Presentation to be Announced

 

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English


更新通知サービス


Premier Sponsors


表示切替:



メール配信サービス